• Investors may be wondering if AbbVie at around US$202 a share still offers value, or if most of the opportunity has already played out.
• The stock has recently seen mixed returns, with a 4.1% decline over the last 7 days, a 1.8% decline over 30 days, and an 11.6% decline year to date. Over 1 year and 5 years, the returns stand at 12.8% and 109.7% respectively.
• Recent headlines have focused on AbbVie's position in the large-cap pharmaceuticals space and how investors are weighing its long term prospects against near term share price moves. This context helps explain why some shareholders are reassessing whether the current price offers enough compensation for the risks they see.
• Right now AbbVie scores a 3 out of 6 on our valuation checks. Next you will see how traditional methods like DCF and multiples compare, followed by a broader way to think about value that goes beyond the headline numbers.

Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today using a required rate of return.

For AbbVie, the DCF model used here is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $18.0b. Analyst and extrapolated projections suggest Free Cash Flow of $26.7b in 2026, rising to an estimated $34.3b in 2030, with Simply Wall St extending the forecasts beyond the period covered by analysts.

Pulling all those projected cash flows together and discounting them back to today produces an estimated intrinsic value of about $418.78 per share. Against the current price of around $202, this model implies AbbVie is trading at a 51.6% discount to that estimate. On this DCF view, the stock appears materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 51.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: AbbVie Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it links what you pay for the stock directly to the earnings the business is generating today. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and a lower P/E when they are more cautious about growth or see higher risk.

AbbVie currently trades on a P/E of 99.7x. That is well above the Biotechs industry average P/E of 17.8x and also higher than the peer group average of 20.9x. On those simple comparisons alone, the stock screens as expensive relative to many alternatives in its space.

Simply Wall St’s Fair Ratio for AbbVie is 36.7x, which is their proprietary view of what a more appropriate P/E might be after factoring in the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics. This Fair Ratio can be more helpful than a plain peer or industry comparison because it tries to adjust for the specific qualities of AbbVie rather than treating all companies in the sector as alike. With the current P/E of 99.7x sitting well above the Fair Ratio of 36.7x, this framework suggests the stock looks overvalued on earnings.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your AbbVie Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you tie your view of AbbVie’s story to explicit forecasts and a fair value, then compare that fair value to today’s price. The platform updates your Narrative automatically as new news or earnings land. One investor might build a higher fair value Narrative closer to the US$299 analyst target based on confidence in immunology and neuroscience growth, while another might lean toward the US$184 end of the range if more focused on patent and pricing risks. Both can quickly see whether their own fair value suggests the stock looks cheap or expensive at the current market price.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.